Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.35 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900510 | 0.80 | KDM4E (0.41) | LMNAPTPRZ1ALDH1A1KDM4ETDP1 | |
| SCHEMBL16956228 | 0.76 | CYP1A1 (0.39) | LMNAALDH1A1TP53 | |
| SCHEMBL900704 | 0.72 | KDM4E (0.35) | KCNK2KCNK10PTPRZ1ALDH1A1KDM4E | |
| SCHEMBL900778 | 0.72 | KDM4E (0.35) | PTPRZ1ALDH1A1KDM4ETDP1 | |
| SCHEMBL63193 | 0.72 | ALDH1A1 (0.59) | ALDH1A1 | |
| SCHEMBL515476 | 0.72 | ACHE (0.45) | LMNAKCNK2KCNK10ALDH1A1RXFP1 | |
| SCHEMBL96299 | 0.71 | RAB9A (0.38) | LMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL20526166 | 0.71 | KDM4E (0.34) | PTPRZ1ALDH1A1KDM4ETDP1 | |
| SCHEMBL1067737 | 0.71 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL28089288 | 0.70 | ALDH1A1 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | claimed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | claimed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | claimed |
| CN-104245689-A | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL CO | 2014-12-24 | — | — | CN | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | LMNA 3400/4885KCNK2 4498/4885KCNK10 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.